CHRS SEC Filings: 8-K, 10-Q, S-3 & 424B – Coherus Oncology

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 11, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWCoherus Oncology Reports Q3 2026 Financial Results and Strategic Prioritization Plan

Nov 9, 2026

8-K

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

Oct 29, 2026

8-K

Coherus Oncology, Inc. Enters Into $50 Million "At-the-Market" Equity Offering Program

Aug 28, 2026

8-K

Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights (CVRs)

Aug 17, 2026

8-K

Coherus Oncology Enters into $55 Million Senior Secured Term Loan Agreement

Aug 17, 2026

8-K

Coherus Oncology Reports Q2 2026 Financial Results and Pipeline Progress

Aug 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

[No Baby Shelf]* August 2026 ATM | Offering amount: $50,000,000 | Bank: Leerink Partners LLC

Aug 28, 2026

424B3

UPDATE TO PRIOR PROSPECTUS | Offering amount: $64,880,054 | Bank: TD Securities (USA) LLC

Aug 28, 2026

424B5

REGISTERED OFFERING

Feb 13, 2026

424B5

PENDING FIXED PRICE OFFERING | Bank: TD Cowen, Guggenheim Securities, Oppenheimer & Co.

Feb 12, 2026

424B5

January 2026 ATM | Offering amount: $64,880,054 | Bank: TD Cowen

Jan 23, 2026

424B5

ATM | Offering amount: $78,407,207 | Amount sold to date: $14,100,000

Sep 12, 2023

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 5, 2026

S-3

November 2025 SHELF

Nov 13, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Nov 13, 2025

SC TO-I/A

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

May 15, 2025

SC TO-I

Form SC TO-I - Tender offer statement by Issuer

Apr 16, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 8, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 28, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 5, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 14, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 9, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Jul 27, 2026

Satvat Ali J. (Reporting)

Jun 9, 2026

Karachun Rita A (Reporting)

Jun 9, 2026

Newcomer Lee Nisley (Reporting)

Jun 9, 2026

Ryan Michael Lee (Reporting)

Jun 9, 2026

O'Donnell-Tormey Jill (Reporting)

Jun 9, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 9, 2025

CORRESP

Form CORRESP - Correspondence

Dec 5, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 13, 2024

CORRESP

Form CORRESP - Correspondence

Sep 6, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 23, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 27, 2023

Coherus Oncology, Inc. CHRS · SEC Filings